Chronic Myeloid Leukemia Market Set for Strong Expansion Through 2034, Driven by Advancing Targeted Therapies and Robust Pipeline Innovations, says DelveInsight

DelveInsight's "Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers a comprehensive analysis of Chronic Myeloid Leukemia (CML), covering historical and projected epidemiology trends along with evolving market dynamics across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

To gain deeper insights into the Chronic Myeloid Leukemia market outlook, treatment landscape, drug adoption trends, and epidemiological patterns, click here: Chronic Myeloid Leukemia Market Forecast https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Chronic Myeloid Leukemia Market Report:
• The Chronic Myeloid Leukemia market is projected to expand at a notable CAGR throughout the forecast period spanning 2020-2034.
• In March 2025, shares of Zydus Lifesciences rose by 3.33% to INR 917.10 following the US FDA's final approval for its generic Dasatinib Tablets in multiple dosage strengths. The approved generic alternative to Sprycel is indicated for adult patients newly diagnosed with Philadelphia chromosome-positive CML, as well as those who have developed resistance or intolerance to earlier therapies such as imatinib.
• In February 2025, Cipla received final approval from the US FDA for its Nilotinib Capsules (50 mg, 150 mg, and 200 mg) intended for the treatment of Philadelphia chromosome-positive Chronic Myeloid Leukemia. The company plans to launch the product in the US market during FY 2025-26.
• In November 2024, Marks Shorla Oncology announced FDA approval of imatinib oral solution (Imkeldi), marking the first liquid oral tyrosine kinase inhibitor approved for use in multiple malignancies, including CML, gastrointestinal stromal tumors (GIST), myelodysplastic syndromes (MDS), myeloproliferative disorders (MPD), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
• Also in November 2024, the US FDA approved a reformulated version of nilotinib, marketed as Danziten, for adults with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase. The approval additionally includes adult patients in chronic or accelerated phases who are resistant or intolerant to prior therapies, including imatinib.
• In October 2024, Novartis secured accelerated approval from the US FDA for Scemblix (asciminib) for treating adults newly diagnosed with Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP).
• In January 2024, Terns Pharmaceuticals anticipated the release of key proof-of-concept data for its investigational CML therapy, TERN-701, by the second half of 2024.
• During January 2024, Novartis reported positive primary analysis results from the Phase III ASC4FIRST trial, which evaluated SCEMBLIX versus investigator-selected preferred TKI therapy in patients newly diagnosed with Philadelphia chromosome-positive CML in the chronic phase.
• Based on estimates from the American Cancer Society, approximately 9,280 new cases of CML were expected to be diagnosed in the United States in 2024, including 5,330 men and 3,950 women.
• According to NICE UK, Chronic Myeloid Leukemia has an annual incidence rate of 4.2 cases per 100,000 people. CML represents nearly 5% of all childhood leukemia cases, and approximately 85-90% of patients are diagnosed during the chronic phase.
• SEER-based estimates suggest that nearly 8,860 new cases of Chronic Myeloid Leukemia were recorded in the United States in 2022.
• Major companies active in the Chronic Myeloid Leukemia space include Novartis, Takeda, Pfizer, Bristol-Myers Squibb, Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, M.D. Anderson Cancer Center, Kartos Therapeutics, Groupe Francophone des Myelodysplasies, University of Jena, Il-Yang Pharm. Co., Ltd., Shenzhen TargetRx, Inc., Astex Pharmaceuticals, Inc., and others.
• Key therapies under development or currently available in the Chronic Myeloid Leukemia market include SCEMBLIX (asciminib), ICLUSIG (ponatinib), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ELVN-001, TERN-701, HQP1351, ABL001, KRT-232, Venetoclax, Imatinib, Radotinib, TGRX-678, Azacitidine, and others.
• The Chronic Myeloid Leukemia market is expected to witness strong growth driven by rising disease prevalence and increasing awareness. Additionally, the introduction of pipeline assets across multiple stages of development is anticipated to significantly reshape market dynamics during the forecast period.

Chronic Myeloid Leukemia Overview
Chronic Myeloid Leukemia (CML) is a hematological malignancy originating in the bone marrow's blood-forming cells. The disease is marked by excessive proliferation of immature myeloid cells, a subtype of white blood cells. CML is characterized by the presence of the Philadelphia chromosome, caused by a chromosomal translocation between chromosomes 9 and 22. This abnormality results in the BCR-ABL1 fusion gene, which produces a protein that drives uncontrolled myeloid cell growth.

Request a free sample of the Chronic Myeloid Leukemia Market Forecast, Size & Share Analysis Report here: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Myeloid Leukemia Epidemiology
The epidemiology section presents a thorough evaluation of historical, current, and projected trends across the seven major markets (7MM) from 2020 to 2034. It examines the drivers behind observed and forecasted patterns by integrating findings from published studies and insights from key opinion leaders. This section also offers an in-depth assessment of diagnosed patient populations and future epidemiological shifts.
Epidemiology Segmentation Includes:
• Overall prevalence of Chronic Myeloid Leukemia
• Severity-based prevalent cases of Chronic Myeloid Leukemia
• Gender-specific prevalence trends
• Diagnosed cases of episodic and chronic Chronic Myeloid Leukemia

Download the report to explore the factors shaping Chronic Myeloid Leukemia epidemiology trends:
https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Drug Uptake and Pipeline Development in Chronic Myeloid Leukemia
The drug uptake section analyzes the adoption rate of newly launched and upcoming therapies in the Chronic Myeloid Leukemia market during the study timeframe. It evaluates drug-wise market penetration, therapy-based patient uptake, and individual product sales performance.
Additionally, the therapeutics assessment identifies agents with rapid uptake and explains the factors contributing to their widespread use. Comparative analyses based on market share further enhance understanding.
The report also provides a comprehensive overview of Chronic Myeloid Leukemia pipeline development activities, highlighting investigational candidates across various clinical stages and the companies spearheading their development. Recent strategic developments, including partnerships, mergers, acquisitions, licensing agreements, and patent activity, are also examined.

Chronic Myeloid Leukemia Therapies and Key Developers
• SCEMBLIX (asciminib): Novartis
• ICLUSIG (ponatinib): Takeda
• TASIGNA (nilotinib): Novartis
• BOSULIF (bosutinib): Pfizer
• SPRYCEL (dasatinib): Bristol-Myers Squibb
• ELVN-001: Enliven Therapeutics
• TERN-701: Terns Pharmaceuticals
• HQP1351: Ascentage Pharma
• ABL001: Novartis
• Asciminib: M.D. Anderson Cancer Center
• KRT-232: Kartos Therapeutics
• Venetoclax: Groupe Francophone des Myelodysplasies
• Imatinib: University of Jena
• Radotinib: Il-Yang Pharm. Co., Ltd.
• TGRX-678: Shenzhen TargetRx, Inc.
• Azacitidine: Astex Pharmaceuticals, Inc.
Explore therapies poised to capture significant market share:
https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Myeloid Leukemia Market Strengths
• High-value therapies with enhanced efficacy, including kinase inhibitors and immunotherapies, are expected to lead the market.
• Innovative agents such as SCEMBLIX (asciminib) offer selective targeting of the ABL myristoyl pocket, resulting in improved safety and tolerability over existing standards of care.

Chronic Myeloid Leukemia Market Opportunities
• Limited therapeutic options for relapsed and refractory CML patients highlight unmet clinical needs.
• Increased participation in clinical trials presents opportunities to evaluate emerging treatments and advance disease management.

Scope of the Chronic Myeloid Leukemia Market Report
• Study Timeline: 2020-2034
• Geographic Coverage: 7MM (United States, EU5-Germany, France, Italy, Spain, United Kingdom-and Japan)
• Leading Companies and Therapies as detailed above
• Therapeutic Assessment of marketed and emerging treatments
• Market Dynamics including drivers and restraints
• Competitive Intelligence tools such as SWOT, PESTLE, Porter's Five Forces, BCG Matrix, and market entry strategies
• Evaluation of unmet needs, KOL insights, analyst perspectives, market access, and reimbursement frameworks

To learn more about companies developing treatments for Chronic Myeloid Leukemia, visit:
https://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction to the Chronic Myeloid Leukemia Market Report
2. Executive Summary
3. SWOT Analysis
4. Patient Share Overview
5. Market Overview Snapshot
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Country-Specific Patient Analysis
9. Current Treatment Practices
10. Unmet Medical Needs
11. Emerging Therapies
12. Market Outlook
13. Country-Wise Market Analysis (2020-2034)
14. Market Access and Reimbursement
15. Market Drivers
16. Market Barriers
17. Appendix
18. Research Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.